Inclisiran, an innovative medicine made by Novartis to lower cholesterol levels, is introduced to the Hainan Boao Lecheng International Medical Tourism Pilot Zone.

The first injection of Inclisiran, an innovative medicine designed by Swiss drug maker Novartis to lower cholesterol levels, was conducted at Boao Super Hospital in the Hainan Boao Lecheng International Medical Tourism Pilot Zone on July 1.

Inclisiran, a long-acting small interfering RNA (siRNA) that works to lower plasma LDL-cholesterol (LDL-C) levels, was approved by the European Union in December 2020 to treat adult hypercholesteremia and mixed dyslipidemia.

The mechanism of the drug action allows patients to receive subcutaneous injections only twice a year to achieve a curative effect.

Inclisiran.

"The year 2021 marks the centenary of the Communist Party of China and the application of Inclisiran in Lecheng is a tribute to the centenary of the CPC and a step forward in promoting the development of China's treatment of cardiovascular diseases," said Gu Gang, director of the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration.

"We hope to introduce more products like Inclisiran to let Chinese patients have access to global advanced medicines and facilities," added Gu.

Gu noted that Novartis is one of the most important cooperative partners of Lecheng, and that the licensed operation of Inclisiran may speed up the process by which Novartis's innovative medicines can enter the Chinese market.

He expressed his hope that Lecheng and Novartis can establish a long-term mechanism to make joint efforts in boosting the development of China's big health industry.